HALIFAX, NS June 12, 2024 – Fortune Bay Corp. (TSXV:FOR) (FWB:5QN) (OTCQB:FTBYF) (“Fortune Bay” or the “Company”) is pleased to announce the commencement of drilling at its Murmac Uranium Project (“Murmac” or the “Project”) on the northern margin of the Athabasca Basin, Saskatchewan. The drilling program is being funded by Aero Energy Limited (TSXV: AERO) (OTC […]
HALIFAX, NS June 4, 2024 – Fortune Bay Corp. (TSXV:FOR) (FWB:5QN) (OTCQB:FTBYF) (“Fortune Bay” or the “Company”) is pleased to announce drill targets for its Murmac Uranium Project (“Murmac or the “Project”) located in northern Saskatchewan. A drilling program is scheduled to commence in the coming days to test up to thirteen (13) of these targets […]
Further to Antler Gold Inc.’s (TSXV: ANTL) (“Antler” or the “Company”) News Release dated May 23, 2024 (the “Erongo Gold News Release”), the transaction contemplated in the Letter of Intent between the Company and Fortress Asset Management LLC, as described in the Erongo Gold News Release, is subject to TSX-V and shareholder approval.
Antler Gold Inc. (“Antler” or the “Company”) (TSX-V:ANTL) is pleased to announce that its subsidiary, Antler Gold Namibia (Pty) Ltd (“Antler Nam”), has signed a binding Letter Of Intent (“LOI”) with Fortress Asset Management LLC (“Fortress” or the “Optionee”), an arms-length private company.
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to advise that it has appointed Dr. Carman Giacomantonio MD, MSc., FRCSC (Cav.) to be the Company’s Chief Medical Officer. Dr. Giacomantonio is a practicing Surgical Oncologist at the QEII Health Sciences Centre and a Professor of Surgery at Dalhousie University. Dr. Giacomantonio leads a productive translational research group at Dalhousie University and has successfully initiated two clinical trials in cancer immunotherapy. He is widely published in the field of cancer immunobiology and immunotherapy research, and a recognized innovator in the field of intra-tumoral cancer immunotherapy. Dr. Giacomantonio currently serves on Sona’s Advisory Board and is the Principal Investigator for Sona’s pre-clinical studies using Sona’s gold nanorods in its Targeted Hyperthermia Therapy (“THT”) for triple negative breast cancer, melanoma, and colorectal cancer. Sona is extremely excited to have Dr. Giacomantonio’s vision and experience to lead the development of our THT-based immunotherapy towards first-in-human clinical trials.
Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) announces that it has been approved for funding totaling approximately $40,000 to support the development of its intellectual property portfolio.
The Company is receiving advisory services and up to $24,894 in funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”) IP Assist program to support the development of an intellectual property strategy for Sona’s proprietary gold nanorods for novel targeted drug delivery concepts with a view to securing new patents.
Halifax, Nova Scotia-(Newsfile Corp. – April 26, 2024) – E-Tech Resources Inc. (TSXV: REE) (FSE: K2I) (“E-Tech” or the “Company“) is pleased to announce the appointment of Christopher Drysdale as interim Chief Executive Officer (“CEO”) of the Company. Mr. Drysdale is an experienced professional with international experience in the mineral and exploration industry. Currently serving as the […]
Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce further positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the “Study”).
Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) announces that it has been approved for funding totaling approximately $40,000 to support the development of its intellectual property portfolio.
The Company is receiving advisory services and up to $24,894 in funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”) IP Assist program to support the development of an intellectual property strategy for Sona’s proprietary gold nanorods for novel targeted drug delivery concepts with a view to securing new patents.
Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) announces positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the “Study”). An update received by the Company indicates that all tumors treated within the Study to date with a single Targeted Hyperthermia Therapy (“THT”) treatment shrunk within the first 24 hours, with an average reduction in size of 80% compared to matched controls.